Tourmaline Bio

Join us for an in-depth investor webinar featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics on November 1st at 9:30 AM ET. He will share his key insights on how human genetic studies are driving innovative approaches for treating high-risk cardiovascular patients, such as IL-6 inhibition. With cardiovascular disease being one of the leading global health challenges, understanding the genetic drivers of cardiovascular risk is crucial to developing therapies that go beyond conventional treatments. Register now to gain valuable insights from an expert in cardiovascular genetics: https://bit.ly/3zOmejF

Now Streaming: New Perspectives in Treating Thyroid Eye Disease (TED) via Eye Health Academy. Tune into this educational webinar on TED as an expert panel of multidisciplinary faculty will share insights and best practices for the diagnosis and treatment of TED, offering approaches to better understand the complexities of this challenging disease. Tourmaline is proud to support this event and encourage continued educational opportunities around this rare disease. Register now to hear the latest perspectives on TED management. Available for 1.0 ACCME/ANCC/AAPA credits. https://bit.ly/486Wv2w

ICYMI: Last week at the Cardiometabolic Health Congress, we shared insights on IL-6 inhibition and inflammatory cardiovascular risk. Check out our posters for more: https://bit.ly/4dRQiZk #CMHC19thAnnual #MeetMeAtCMHC #healthcare

Today, we shared our latest insights at the Cardiometabolic Health Congress in Boston, focusing on inflammatory cardiovascular risk as well as potential therapeutic mechanisms of targeted IL-6 inhibition. Key takeaways from our posters: • Our real-world evidence analysis found low rates of hs-CRP testing in both primary and secondary prevention settings in the US despite robust data supporting the association of CRP with cardiovascular risk. This highlights the need for increased awareness and clinical translational efforts to improve hs-CRP testing. • Our meta-analysis of published studies showed that IL-6 inhibition was associated with reductions in Lp(a). This may represent another potential therapeutic mechanism of IL-6 inhibition among other anti-inflammatory mechanisms previously described. We remain dedicated to advancing innovative approaches that address critical inflammatory drivers of cardiovascular disease. Explore our posters here: https://bit.ly/4dRQiZk #MeetMeAtCMHC #CMHC19thAnnual #MedicalResearch

We’re looking forward to joining the cardiovascular community in Boston at the Cardiometabolic Health Congress from October 17-19 to present our latest insights on IL-6 inhibition and inflammatory cardiovascular risk. For more information on our upcoming presentations, click here: https://bit.ly/3zKx0Yd #MeetMeAtCMHC #CMHC19thAnnual #inflammation

We are excited to announce the formation of Tourmaline’s Cardiovascular Scientific Advisory Board (CV SAB), which brings together leading experts across the fields of cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. The depth and breadth of their collective expertise across atherosclerotic cardiovascular disease (ASCVD), heart failure, vascular medicine, imaging, genetics, and biostatistics will be invaluable as we advance our efforts to develop pacibekitug for cardiovascular diseases. A growing body of evidence continues to support the therapeutic potential of IL-6 inhibition in atherosclerotic cardiovascular diseases, heart failure, ASCVD and beyond. https://bit.ly/3ZXZb0s #business #biotechnology #leadership

Today, on #WorldHeartDay, we are reminded that cardiovascular disease (CVD) is the world’s leading cause of death, claiming more than 20.5 million lives around the globe annually. According to a recent report by the CDC, as many as 33.6% of premature CVD deaths are preventable in just the U.S. alone. According to the World Heart Federation, by making small changes in our daily lives—like improving our diet, staying active, and managing stress—we can take meaningful steps toward better heart health. You can learn more about that here: https://bit.ly/3AUJJaW  At Tourmaline Bio, we’re dedicated to developing therapies that will support high-risk cardiovascular patients who still suffer from major adverse events despite these lifestyle changes and existing medications. We are committed to reducing the global burden of cardiovascular disease. Let’s keep the momentum going. #healthcare #HeartYes

Key findings from a new study reveal high-sensitivity C-reactive protein (hs-CRP) to be a significant biomarker indicating cardiovascular risk. Data from this study, published in the New England Journal of Medicine, underscore the need to reconsider how we assess cardiovascular risk and manage prevention strategies. The fact that inflammation, as indicated by hs-CRP, plays such a significant role suggests that traditional approaches focusing primarily on lipid management may overlook a major contributor to predicting cardiovascular events. Tourmaline is greatly encouraged by this exciting new research, which may indicate the potential of innovative treatments that address inflammation as a primary factor in cardiovascular disease. Explore the full study in NEJM Group: https://bit.ly/4dMxOdC #dataresearch #CVD #innovation

Don’t miss today’s webcast! Join Tourmaline’s CEO, Sandeep Kulkarni, at 3:40 PM ET as he joins a fireside chat at the Cantor Global Healthcare Conference. Tune in to the live webcast to learn more and stay connected with Tourmaline’s vision driving our continued momentum: https://bit.ly/4cZr3Uv Cantor Fitzgerald $TRML #investors #business #CantorHCC

Our CEO, Sandeep Kulkarni, will be participating in a fireside chat at the Cantor Global Healthcare Conference on September 17th at 3:40 pm ET where he will share insights into our strategic vision and clinical progress made during 2024. Register and tune in here: https://bit.ly/4cZr3Uv Cantor Fitzgerald $TRML #investors #CantorHCC #biotechnology